SCHEMBL6887342

SCHEMBL6887342

COc1ccc2c(c1)-c1nc(/N=C\N(C)C)sc1CC2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.67
ALDH1A1 P00352 8/20 0.67
KDM4E B2RXH2 6/20 0.67
GAA P10253 3/20 0.67
BLM P54132 1/20 0.62
MPI P34949 2/20 0.60
HPGD P15428 2/20 0.60
THRB P10828 2/20 0.60
TP53 P04637 7/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
RAB9A P51151 2/20 0.54
RXFP1 Q9HBX9 1/20 0.48
ADORA1 P30542 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11955704 0.85 MAPT (0.48) MAPTALDH1A1KDM4EGAABLM
SCHEMBL6885965 0.75 MAPT (1.00) MAPTALDH1A1KDM4EGAAMPI
SCHEMBL6886816 0.72 MAPT (0.60) MAPTALDH1A1KDM4EGAABLM
SCHEMBL11895247 0.72 MAPT (0.60) MAPTALDH1A1KDM4EGAABLM
SCHEMBL12797289 0.69 MAPT (0.85) MAPTALDH1A1KDM4EGAAMPI
SCHEMBL1815237 0.65 ADORA1 (0.97) MAPTALDH1A1KDM4EMPIHPGD
Bromide SCHEMBL2762927 0.64 ADORA1 (0.95) MAPTALDH1A1KDM4EMPIHPGD
SCHEMBL13202414 0.62 CYP1A2 (0.56) MAPTALDH1A1KDM4EMPIHPGD
SCHEMBL1509479 0.61 ALDH1A1 (0.56) MAPTALDH1A1KDM4EGAABLM
SCHEMBL7000669 0.61 KDM4E (0.80) MAPTALDH1A1KDM4EMPITP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders THE JOHNS HOPKINS UNIVERSITY (US) 2019-11-12 US disclosed
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-02 US disclosed
WO-2011017519-A2 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS METAP1, METAP2, ENPEP MAPT 1551/4885ALDH1A1 1430/4885KDM4E 3317/4885
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders METAP1, METAP2, ENPEP MAPT 1551/4885ALDH1A1 1430/4885KDM4E 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.